1
|
Mohzari YA, Alamer A, Alattas M, Alrashed AA, Alshehab NA, Alkhaldi TK, Alamer AA, Asdaq SM, Aljefri D, Alajami HN, Alsowaida YS, Mathew M, AlMusawa MI, Alomar M, Alharbi RY, Khuwaja M, Bamogaddam RF, Alharthi AH, Faqihi AY, Alrumayyan BF, Alshareef A, Alhassan BM, Damfu NY, Alajmi GS, Albujaidy A, Alghalbi M, Alajlan SA, Abraham I, Almulhim AS. Tocilizumab effectiveness in mechanically ventilated COVID-19 patients (T-MVC-19 Study): a multicenter real-world evidence. Expert Rev Anti Infect Ther 2022; 20:1037-1047. [PMID: 35209783 PMCID: PMC8935451 DOI: 10.1080/14787210.2022.2046462] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Accepted: 02/21/2022] [Indexed: 01/08/2023]
Abstract
BACKGROUND This study aimed to evaluate the effectiveness of tocilizumab in mechanically ventilated patients with coronavirus disease 2019 (COVID-19). RESEARCH DESIGN AND METHODS This retrospective multicenter study included adults (≥18 years) diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by real-time polymerase chain reaction (RT-PCR) from nasopharyngeal swab, and requiring invasive mechanical ventilation during admission. Survival analyses with inverse propensity score treatment weighting (IPTW) and propensity score matching (PSM) were conducted. To account for immortal bias, we used Cox proportional modeling with time-dependent covariance. Competing risk analysis was performed for the extubation endpoint. RESULTS A total of 556 (tocilizumab = 193, control = 363) patients were included. Males constituted the majority of the participants (69.2% in tocilizumab arm,74.1% in control arm). Tocilizumab was not associated with a reduction in mortality with hazard ratio [(HR) = 0.82,95% confidence interval (95%CI): 0.62-1.10] in the Inverse propensity score weighting (IPTW) analysis and (HR = 0.86,95% CI: 0.64-1.16) in the PSM analysis. However, tocilizumab was associated with an increased rate of extubation (33.6%) compared to the control arm (11.9%); subdistributional hazards (SHR) = 3.1, 95% CI: 1.86-5.16). CONCLUSIONS Although tocilizumab was not found to be effective in reducing mortality, extubation rate while on mechanical ventilation was higher among tocilizumab treated group.
Collapse
Affiliation(s)
- Yahya A. Mohzari
- Department of Clinical Pharmacy, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia; King Saud Medical City, Riyadh, Saudi Arabia
| | - Ahmad Alamer
- Department of Clinical Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia; Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA
| | - Majda Alattas
- Department of Clinical Pharmacy, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia
| | - Ahmed A. Alrashed
- Department of Pharmaceutical Services, Main hospital, King Fahad Medical City, Riyadh, Saudi Arabia
| | | | - Turkiah K. Alkhaldi
- Department of Pharmaceutical Service, Main Pharmacy, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Amnah A. Alamer
- Department of Internal Medicine, King Faisal University, Al-Ahsa, Saudi Arabia; Department of Infectious Diseases, McMaster University, Hamilton, Ohio, Canada
| | - Syed M.B Asdaq
- Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia
| | - Doaa Aljefri
- Department of Pharmacy, King Abdulaziz Medical City, Jeddah, Saudi Arabia
| | - Hamdan N. Alajami
- Pharmaceutical Care Department, King Saud Medical City, Riyadh, Saudi Arabia
| | - Yazed S. Alsowaida
- Department of Clinical Pharmacy, College of Pharmacy, Hail University, Hail, Saudi Arabia; Department of Pharmacy, Brigham and Women’s Hospital, Boston, MA, USA
| | - Maya Mathew
- Department of Clinical Pharmacy, King Saud Medical City, Riyadh, Saudi Arabia
| | - Mohammed I. AlMusawa
- Division of Pharmaceutical Care, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia
| | - Mukhtar Alomar
- Dammam Medical Complex, First Health Cluster in Eastern Province, Saudi Arabia
| | - Raghad Y. Alharbi
- Department of Clinical Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia
| | - Malik Khuwaja
- Division of Pharmaceutical Care, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia
| | - Reem F. Bamogaddam
- Department of Clinical Pharmacy, King Saud Medical City, Riyadh, Saudi Arabia
| | - Ashwaq H. Alharthi
- Department of Pharmacy Services, King Saud University Medical City, Riyadh, Saudi Arabia
| | - Aisha Y. Faqihi
- Department of Pharmacy, King Fahad Medical City, Riyadh, Saudi Arabia
| | | | - Abeer Alshareef
- Department of Pharmacy Services, King Saud University Medical City, Riyadh, Saudi Arabia
| | - Batool M. Alhassan
- Department of Clinical Pharmacy, Almoosa Specialist Hospital, Al-Ahasa, Saudi Arabia
| | - Nader Y. Damfu
- Department of Pharmaceutical Care, King Abdulaziz Medical City, Jeddah, Saudi Arabia
| | - Ghada S. Alajmi
- Department of Pharmacy Services, King Saud University Medical City, Riyadh, Saudi Arabia
| | - Asma Albujaidy
- Department of Clinical Pharmacy Service, Prince Mohammed bin Abdulaziz Hospital, Riyadh, Saudi Arabia
| | - Maram Alghalbi
- Department of Pharmaceutical Services, Clinical Pharmacy, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Saleh A Alajlan
- Department of Pediatric Dentistry, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Ivo Abraham
- Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA; Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA
| | - Abdulaziz S. Almulhim
- Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia
| |
Collapse
|
3
|
Robertson SE, Leith A, Schmid CH, Dahabreh IJ. Assessing Heterogeneity of Treatment Effects in Observational Studies. Am J Epidemiol 2021; 190:1088-1100. [PMID: 33083822 DOI: 10.1093/aje/kwaa235] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2019] [Revised: 10/12/2020] [Accepted: 10/16/2020] [Indexed: 01/21/2023] Open
Abstract
Here we describe methods for assessing heterogeneity of treatment effects over prespecified subgroups in observational studies, using outcome-model-based (g-formula), inverse probability weighting, doubly robust, and matching estimators of subgroup-specific potential outcome means, conditional average treatment effects, and measures of heterogeneity of treatment effects. We compare the finite-sample performance of different estimators in simulation studies where we vary the total sample size, the relative frequency of each subgroup, the magnitude of treatment effect in each subgroup, and the distribution of baseline covariates, for both continuous and binary outcomes. We find that the estimators' bias and variance vary substantially in finite samples, even when there is no unobserved confounding and no model misspecification. As an illustration, we apply the methods to data from the Coronary Artery Surgery Study (August 1975-December 1996) to compare the effect of surgery plus medical therapy with that of medical therapy alone for chronic coronary artery disease in subgroups defined by previous myocardial infarction or left ventricular ejection fraction.
Collapse
|
4
|
Samuel M, Batomen B, Rouette J, Kim J, Platt RW, Brophy JM, Kaufman JS. Evaluation of propensity score used in cardiovascular research: a cross-sectional survey and guidance document. BMJ Open 2020; 10:e036961. [PMID: 32847911 PMCID: PMC7451534 DOI: 10.1136/bmjopen-2020-036961] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND Propensity score (PS) methods are frequently used in cardiovascular clinical research. Previous evaluations revealed poor reporting of PS methods, however a comprehensive and current evaluation of PS use and reporting is lacking. The objectives of the present survey were to (1) evaluate the quality of PS methods in cardiovascular publications, (2) summarise PS methods and (3) propose key reporting elements for PS publications. METHODS A PubMed search for cardiovascular PS articles published between 2010 and 2017 in high-impact general medical (top five by impact factor) and cardiovascular (top three by impact factor) journals was performed. Articles were evaluated for the reporting of PS techniques and methods. Data extraction elements were identified from the PS literature and extraction forms were pilot tested. RESULTS Of the 306 PS articles identified, most were published in Journal of the American College of Cardiology (29%; n=88), and Circulation (27%, n=81), followed by European Heart Journal (15%; n=47). PS matching was performed most often, followed by direct adjustment, inverse probability of treatment weighting and stratification. Most studies (77%; n=193) selected variables to include in the PS model a priori. A total of 38% (n=116) of studies did not report standardised mean differences, but instead relied on hypothesis testing. For matching, 92% (n=193) of articles presented the balance of covariates. Overall, interpretations of the effect estimates corresponded to the PS method conducted or described in 49% (n=150) of the reviewed articles. DISCUSSION Although PS methods are frequently used in high-impact medical journals, reporting of methodological details has been inconsistent. Improved reporting of PS results is warranted and these proposals should aid both researchers and consumers in the presentation and interpretation of PS methods.
Collapse
Affiliation(s)
- Michelle Samuel
- Center for Health Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
- Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada
| | - Brice Batomen
- Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada
| | - Julie Rouette
- Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada
| | - Joanne Kim
- Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada
| | - Robert W Platt
- Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada
| | - James M Brophy
- Center for Health Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
- Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada
| | - Jay S Kaufman
- Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada
| |
Collapse
|